Table 2.
Preclinical study examples demonstrating the use of in situ-forming hydrogels for delivery of cancer vaccines.
| Hydrogel | Injection location | Gelation-stimuli | Antigen | Other loaded drugs/immunotherapy | Tumor model | Citation |
|---|---|---|---|---|---|---|
| PEG crosslinked melittin-peptide | i.t. | Self-assembly | Ultrafiltered retentate from irradiated cells | Doxorubicin, melittin | B16F10; LLC; MC38 | [64] |
| self-assembled poly(L-valine) | s.c. | Self-assembly | Tumor cell lysates | TLR3 agonist (poly(I:C) | B16 | [203] |
| PEG-b-poly(L-alanine) | s.c. | Self-assembly | Tumor cell lysates | GM-CSF; Anti-CTL-A-4; anti-PD-1 (encapsulated in hydrogel) | B16F10; 4T-1 | [111] |
| polymerized phenylboronic acid (pPBA)-based | Contralateral flank | Mixture of components from two syringes | Tumor cell lysate | Mannan | 4T1 | [204] |
| Silk hydrogel | s.c. | Ultrasound | Hepa1−6 liver cancer-specific neoantigen | TLR9 agonist (CPG-ODN); STING; | Hepa1−6 | [113] |
| mPEG-OVApeptide-AuNPs + ⍺-cyclodextrin | s.c. | Complexation between alpha-CD and PEG before injection. Shear thinning | OVApeptide | CPG | B16-OVA | [108] |
| PDLLA-PEG-PDLLA | s.c. | Temperature | Tumor cell lysates | GM-CSF, CpG-ODN | B16F10; CT26 | [55] |